全文获取类型
收费全文 | 77384篇 |
免费 | 7529篇 |
国内免费 | 2847篇 |
专业分类
耳鼻咽喉 | 171篇 |
儿科学 | 948篇 |
妇产科学 | 548篇 |
基础医学 | 4883篇 |
口腔科学 | 720篇 |
临床医学 | 6958篇 |
内科学 | 8962篇 |
皮肤病学 | 1239篇 |
神经病学 | 2674篇 |
特种医学 | 890篇 |
外国民族医学 | 9篇 |
外科学 | 2573篇 |
综合类 | 10759篇 |
现状与发展 | 6篇 |
一般理论 | 3篇 |
预防医学 | 4849篇 |
眼科学 | 817篇 |
药学 | 32032篇 |
43篇 | |
中国医学 | 4179篇 |
肿瘤学 | 4497篇 |
出版年
2024年 | 97篇 |
2023年 | 1122篇 |
2022年 | 1421篇 |
2021年 | 2627篇 |
2020年 | 2697篇 |
2019年 | 2698篇 |
2018年 | 2717篇 |
2017年 | 3093篇 |
2016年 | 2939篇 |
2015年 | 2896篇 |
2014年 | 4988篇 |
2013年 | 7942篇 |
2012年 | 5001篇 |
2011年 | 5273篇 |
2010年 | 4174篇 |
2009年 | 3636篇 |
2008年 | 3475篇 |
2007年 | 3543篇 |
2006年 | 3246篇 |
2005年 | 2896篇 |
2004年 | 2494篇 |
2003年 | 2274篇 |
2002年 | 1805篇 |
2001年 | 1651篇 |
2000年 | 1289篇 |
1999年 | 1068篇 |
1998年 | 1000篇 |
1997年 | 947篇 |
1996年 | 752篇 |
1995年 | 756篇 |
1994年 | 686篇 |
1993年 | 598篇 |
1992年 | 644篇 |
1991年 | 547篇 |
1990年 | 458篇 |
1989年 | 397篇 |
1988年 | 370篇 |
1987年 | 387篇 |
1986年 | 277篇 |
1985年 | 545篇 |
1984年 | 425篇 |
1983年 | 361篇 |
1982年 | 303篇 |
1981年 | 272篇 |
1980年 | 193篇 |
1979年 | 150篇 |
1978年 | 151篇 |
1977年 | 111篇 |
1976年 | 94篇 |
1975年 | 85篇 |
排序方式: 共有10000条查询结果,搜索用时 506 毫秒
31.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
32.
33.
目的 研究血清窖蛋白-1 (Cav-1) 在慢性阻塞性肺疾病 (COPD) 相关肺动脉高压 (PAH) 患者中的表达及其意义。方法 选取稳定期COPD患者65例, 根据是否合并PAH分成COPD组 [肺动脉收缩压 (PASP) <40 mmHg, 35例] 及COPD-PAH组 (PASP ≥40 mmHg, 30例)。另选取在本院健康体检的志愿者30例作为对照组。对比各组基线资料、 动脉血气分析、 肺功能指标, 以及血清Cav-1、 白细胞介素 (IL) -6和肿瘤坏死因子-α (TNF-α) 的表达水平。绘制受试者工作特征 (ROC) 曲线, 评价Cav-1对COPD合并PAH的诊断价值。结果 COPD-PAH组与COPD组第一秒用力呼吸容积 (FEV1) /用力肺活量 (FVC)、 FEV1占预计值百分比 (FEV1%) 及氧分压 [p (O2 )] 低于对照组, 而二氧化碳分压 [p (CO2 )]、 PASP均高于对照组 (P<0.01)。COPD-PAH组p (O2 ) 低于COPD组, p (CO2 )、 PASP均高于COPD 组 (P<0.01)。对照组、 COPD组及COPD-PAH组Cav-1表达水平呈逐渐降低趋势, 而IL-6、 TNF-α表达水平呈逐渐升高趋势 (P<0.01)。血清Cav-1诊断COPD合并PAH的ROC曲线下面积为0.902 (0.821~0.955), 最佳截断值为 6.66 μg/L, 此时诊断敏感度为76.7%, 特异度为85.7%, 与多普勒超声诊断仪测量PASP结果比较一致性较好 (Kappa 值=0.627)。结论 血清Cav-1在COPD相关PAH患者表达明显下调, 可以作为预测COPD相关PAH的新型血清标志物。 相似文献
34.
35.
36.
Mayuko Kinoshita Haruka Kaneko Lizu Liu Masashi Nagao Ryo Sadatsuki 《Modern rheumatology / the Japan Rheumatism Association》2019,29(1):157-164
Objectives: To examine the factors associated with increase in lumbar spine bone mineral density (LS-BMD) by bisphosphonates (BPs) with active vitamin D analog (aVD).Methods: Two independent postmenopausal osteoporotic patients treated by BPs with aVD for 24 months (Study 1: n?=?93, Study 2: n?=?99) were retrospectively analyzed.Results: In Study 1, LS-BMD of the patients significantly increased for 24 m (5.4%, p?.001). A multiple regression analysis among baseline characteristics revealed that serum calcium (sCa: 8.5–10.5?mg/dL) was associated with an increased LS-BMD by treatment (r2: 0.088, p?=?.02). While average sCa of the patients was 9.2?mg/dL before treatment, it increased time-dependently to 9.6?mg/dL for 24 m by treatment. As each patient had their LS-BMD five times during the study, there were four instances of %LS-BMD in each patient, resulting in 372 instances of %LS-BMD in Study 1. The smallest Akaike’s information criterion value for the most appropriate cut-off levels of sCa for %LS-BMD by treatment every 6 m was 9.3?mg/dL. The %LS-BMD by treatment for 6 m during 24 m period in patients with sCa ≥9.3?mg/dL (1.5%) was significantly higher than that in patients with sCa <9.3?mg/dL (0.8%, p?=?.038). The results of Study 2 were similar to those of Study 1, confirming the phenomena observed.Conclusion: sCa was associated with an increased LS-BMD by BPs with aVD. 相似文献
37.
38.
血吸虫病是一种严重危害人类健康、影响社会经济发展的重大传染病,为全球公共卫生负担和危害最严重的被忽视的热带病之一。吡喹酮是20世纪70年代研制出的一种高效、低毒、价廉的广谱抗蠕虫口服药,为世界卫生组织(WHO)推荐的抗血吸虫的首选药物。吡喹酮在血吸虫病流行区现场大规模反复使用已超过40年,血吸虫是否会对吡喹酮产生抗药性引起国际社会极大担忧,为学术界关注的热点科学问题。针对血吸虫病防治中这一重大需求,自1996年起, 在国家科技支撑计划、国家自然科学基金、江苏省自然科学基金等项目基金资助下,我们在血吸虫病流行区现场和实验室,对血吸虫在吡喹酮药物的压力是否会产生抗药性、抗性虫株的生物学特性、抗性的检测、吡喹酮抗性的交叉抗药性及抗药性的预防和控制等科学问题进行较为系统的研究,本文就其研究及其意义作一概述。 相似文献
39.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
40.
It is hypothesized that persons who use drugs (PWUD) in Vietnam who are also HIV-positive may face additional challenges in psychosocial outcomes, and these challenges may extend to their family members. In this study, we examined depressive symptoms, stigma, social support, and caregiver burden of HIV-positive PWUD and their family members, compared to the outcomes of HIV-negative PWUD and their family members. Baseline, 3-month, and 6-month assessment data were gathered from 83 PWUD and 83 family members recruited from four communes in Phú Th? Province, Vietnam. For PWUD, although we observed a general decline in overall stigma over time for both groups, HIV-positive PWUD consistently reported significantly higher overall stigma for all three periods. Depressive symptoms among family members in both groups declined over time; however, family members of HIV-positive PWUD reported higher depressive symptoms across all three periods. In addition, family members of HIV-positive PWUD reported lower levels of tangible support across all three periods. Caregiver burden among family members of HIV-positive PWUD increased significantly over time, whereas the reported burden among family members of HIV-negative PWUD remained relatively unchanged. The findings highlight the need for future interventions for PWUD and family members, with targeted and culturally specific strategies to focus on the importance of addressing additional stigma experienced by PWUD who are HIV-positive. Such challenges may have direct negative impact on their family members' depressive symptoms, tangible support, and caregiver burden. 相似文献